Summit Therapeutics Inc. Announces Board and Executive Changes
Ticker: SMMT · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $540,000, $600,000, $618,000, $412 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Summit Therapeutics shakes up board and exec pay. Big changes coming?
AI Summary
Summit Therapeutics Inc. announced on January 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. These changes are effective as of January 22, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- January 22, 2025 (date) — Date of Earliest Event Reported
- 601 Brickell Key Drive, Suite 1000 (address) — Principal Executive Offices
- Miami, FL 33131 (address) — Principal Executive Offices
FAQ
Who are the specific directors or officers who have departed from Summit Therapeutics Inc.?
The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.
Who are the newly elected directors to the board of Summit Therapeutics Inc.?
The filing states that new directors have been elected but does not provide their names in the provided text.
What specific changes have been made to the compensatory arrangements of certain officers?
The filing mentions updates to compensatory arrangements but does not detail the specifics of these changes in the provided text.
What is the effective date of these board and executive changes?
The earliest event reported is dated January 22, 2025, indicating this is the effective date for the reported changes.
What is the primary business of Summit Therapeutics Inc. according to the filing?
Summit Therapeutics Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-24 16:23:52
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
- $540,000 — ch receive a cash bonus in an amount of $540,000 with respect to the 2024 fiscal year, p
- $600,000 — anganeh and Mr. Soni will increase from $600,000 to $618,000. Item 8.01 Other Events.
- $618,000 — Mr. Soni will increase from $600,000 to $618,000. Item 8.01 Other Events. As of Dece
- $412 million — tments of the Company was approximately $412 million. This included the repayment of outstan
- $31.8 million — tanding principal and interest totaling $31.8 million from a related party loan that was prev
Filing Documents
- smmt-20250122.htm (8-K) — 28KB
- 0001599298-25-000038.txt ( ) — 180KB
- smmt-20250122.xsd (EX-101.SCH) — 2KB
- smmt-20250122_def.xml (EX-101.DEF) — 14KB
- smmt-20250122_lab.xml (EX-101.LAB) — 25KB
- smmt-20250122_pre.xml (EX-101.PRE) — 15KB
- smmt-20250122_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As of December 31, 2024, the preliminary unaudited balance of aggregate cash, cash equivalents, and short-term investments of the Company was approximately $412 million. This included the repayment of outstanding principal and interest totaling $31.8 million from a related party loan that was previously outstanding, as disclosed in the Company's Form 10-Q for the quarter ended September 30, 2024, filed on October 30, 2024. This amount is preliminary, unaudited and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in the Company's consolidated financial statements for the year ended December 31, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: January 24, 2025 By: /s/ Manmeet S. Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)